'On consolidated basis

Quarter ended September 2025 compared with Quarter ended September 2024.

Net sales (including other operating income) of Dr Reddys Laboratories has increased 9.83% to Rs 8828.3 crore.  Sales of Pharmaceutical Services segment has gone up 7.94% to Rs 1,207.90 crore (accounting for 13.36% of total sales).  Sales of Global Generics segment has gone up 9.21% to Rs 7,823.50 crore (accounting for 86.53% of total sales).  Sales of Others segment has gone down 42.46% to Rs 10.30 crore (accounting for 0.11% of total sales).  Inter-segment sales came down from Rs 262.30 crore to Rs 213.40 crore.  

Profit before interest, tax and other unallocable items (PBIT) has jumped 0.77% to Rs 4,814.20 crore.  PBIT of Pharmaceutical Services segment fell 32.33% to Rs 170.60 crore (accounting for 3.54% of total PBIT).  PBIT of Global Generics segment rose 2.81% to Rs 4,643.10 crore (a...

• 

  (13-Jan-2026)

  HCL Technologies

  Revenue up 13.3% YoY to Rs 33872 crore in Q3FY2026
• 

  (13-Jan-2026)

  Tata Consultancy Services

  Revenue up 4.9% YoY to Rs 67087 crore in Q3FY2026
• 

  (12-Jan-2026)

  Krishana Phoschem

  Revenue up 116.8% YoY to Rs 659 crore in Q3FY2026
• 

  (11-Jan-2026)

  Avenue Supermarts

  Revenue up 13.3% YoY to Rs 18100.9 crore, Net profit up 18.3% yoy to Rs 855.9 crore in Q3FY2026